Healthentia

The predictive capabilities of traditional, vital-based biomarkers on trial outcomes has been under investigation in clinical trials. However, Real World Data is much more than measured vitals: patient-reported outcomes and physical measurements from trial participants’ lifestyles can provide us with extended biomarkers. Can they be useful in predicting future patient reported outcomes or even trial outcomes? Can they be used to model patients or to cluster them into behavioural phenotypes? These are questions addressed under the framework of the workshop, where we will see how AI can support traditional industries, such as Life Sciences, as well as Health, Wellbeing and Ageing. We will also present commercial applications and R&D projects, discussing the challenges and opportunities through the introduction of AI.

The predictive capabilities of traditional, vital-based biomarkers on trial outcomes has been under investigation in clinical trials. However, Real World Data is much more than measured vitals: patient-reported outcomes and physical measurements from trial participants’ lifestyles can provide us with extended biomarkers. Can they be useful in predicting future patient reported outcomes or even trial outcomes? Can they be used to model patients or to cluster them into behavioural phenotypes? These are questions addressed under the framework of the workshop, where we will see how AI can support traditional industries, such as Life Sciences, as well as Health, Wellbeing and Ageing. We will also present commercial applications and R&D projects, discussing the challenges and opportunities through the introduction of AI.

Agenda

• Welcome notes by Prof.dr.ir. Hermie Hermens (University of Twente) & Dr. Sofoklis Kyriazakos (Innovation Sprint)
• Inspiring keynote, Christina Kyriakopoulou (European Commission, DG-RTD)
• Modeling a treatment protocol with little clinical data, Rom Langerak (University of Twente)
• Startup talk: Healthentia.com, Sofoklis Kyriazakos (Innovation Sprint)
• Startup talk: BowheadHealth.com, Francisco Diaz-Mitoma (Bowhead Health)
• Defining Biomarkers & Behavioral Phenotypes, Alfredo Cesario & Aristodemos Pnevmatikakis (Innovation Sprint)
• MDR impact on Software as Medical Devices, Kyun Thibaut (COVARTIM)
• Generator project, Vincenzo Valentini (Policlinico Gemelli / UCSC)
• AI-driven clinical study APACHE (cervical cancer), Vincenzo Valentini (Policlinico Gemelli / UCSC)
• AI-driven clinical study PADAWAN (Non Alcoholic Fatty Liver Disease), Luca Miele (Policlinico Gemelli / UCSC)
• Intelligent triage for low back pain, Wendy Oude Nijeweme – d’Hollosy (University of Twente)
• Towards holistic profiling and personalized cancer treatment, Annemieke Witteveen (University of Twente)
• Pitches from R&D projects
  • H2020 EU-STANDS4PM, Marc Kirschner (FZ-Juelich)
  • H2020 REPO-TRIAL, Harald Schmidt (FARMACO)
  • H2020 INFINITECH, Christiane Grundloh (RRD)
  • H2020 COUCH, Harm op den Akker (RRD)
  • H2020 PANACEA, Aristodemos Pnevmatikakis (Innovation Sprint)
  • H2020 CO-ADAPT, Konstantina Kostopoulou (Innovation Sprint)
• Panel discussion: How AI can be integrated to Life Sciences and Healthcare

when & where

• 17 December 2019
• 09.00 - 17.00
• The TechMed Centre (Technohal building 18), Auditorium (TL 1133)
  
  On the campus of The University of Twente, Drienerlolaan 5, Enschede, The Netherlands; Route

FREE registration here: https://www.utwente.nl/en/techmed/forms/registration-ai-event/

Healthentia is an advanced ePRO (electronic Patient Reported Outcomes) platform that assists the Clinical Research industry to efficiently access Real World Data (RWD) and Lifestyle patterns from IoT devices during studies, thus achieving up to 30% in cost savings and accelerating the drug development process for up to 2 years. Further to the advanced ePRO capabilities, Healthentia is utilizing AI algorithms during clinical studies to predict outcomes based on derived behavioral biomarkers that deliver models of digital twin phenotypes. This pioneering approach will allow Pharmaceutical companies to simulate optimized studies with synthetic data based on previous clinical trials and deliver personalized interventions of high effectiveness. Healthentia is currently validated and used by a Top5 Pharmaceutical company in an observational study, while there are 2 AI-driven studies designed, expected to be launched in 2020/Q1.